DK3038622T3 - Heterocykliske forbindelser og fremgangsmåder til anvendelse - Google Patents
Heterocykliske forbindelser og fremgangsmåder til anvendelse Download PDFInfo
- Publication number
- DK3038622T3 DK3038622T3 DK14839213.7T DK14839213T DK3038622T3 DK 3038622 T3 DK3038622 T3 DK 3038622T3 DK 14839213 T DK14839213 T DK 14839213T DK 3038622 T3 DK3038622 T3 DK 3038622T3
- Authority
- DK
- Denmark
- Prior art keywords
- thiazol
- phenyl
- trifluoromethanesulfonamide
- chloro
- linear
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Claims (13)
1. Forbindelse af (a) formlerne (la) eller (Ib):
eller et farmaceutisk acceptabelt salt deraf, hvor: A er enten: i. et aryl eller heteroaryl, hver med kun en ring, substitueret med 1, 2, eller 3 substituenter valgt fra gruppen bestående af halogen, CN, CF3, OH, C1-C6 lineær eller forgrenet alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C1-C6 lineær eller forgrenet hydroxyalkyl, C1-C3 lineær eller forgrenet alkoxy, C3-C6 cycloalkylmethyl, -(CH2)mCF3, =0, -CH2OCH3, -OBn, -CO2H, - C02-Alkyl, -NR10R11, og -CONR10R11; eller II. et aryl eller heteroaryl, hver med mere end en ring, eventuelt substitueret med 1, 2, eller 3 substituenter valgt fra gruppen bestående af halogen, CN, CF3, OH, C1-C6 lineær eller forgrenet alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C1-C6 lineær eller forgrenet hydroxyalkyl, C1-C3 lineær eller forgrenet alkoxy, C3-C6 cycloalkylmethyl, -(CH2)mCF3, =0, -CH2OCH3, -CH2OH, -OBn, -CO2H, -C02-Alkyl, -NR10R11, og -CONR10R11; hver Rc4, Res, og Rce, er uafhængigt hydrogen, halogen, CN, CF3, OH, C1-C3 lineær eller forgrenet alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C1-C3 lineær eller forgrenet alkoxy, -CO2H, -CONR10R11, eller - NHCONH2; eller er taget med Rc7 for at danne delen
Rc7 er hydrogen, C1-C6 lineær eller forgrenet alkyl, C1-C6 lineær eller forgrenet hydroxyalkyl, -(CR9aR9b)mNR10Rll, -CCte-Alkyl, -(CR9aR9b)mO-Alkyl, - (CR9aR9b)m0P03Na2, “ (CR9aR9b)n70(CR9aR9b)n0-Alkyl, -(CR9aR9b)m0(C = 0)-Alkyl, -(CR9aR9b)n70(CR9aR9b)n0(C=0)-Alkyl, -(C=0)CH=CH2, -S02Rc8·; eller er taget med en af Rc4, Res eller Res for at danne delen
Rce er et lineært eller forgrenet C1-C6 perhaloalkyl, et lineært eller forgrenet C2-C6 perhaloalkenyl, et lineært eller forgrenet C2-C6 perhaloalkynyl, et lineært eller forgrenet C1-C6 alkyl med mindst et halogenatom, et lineært eller forgrenet C2-C6 alkenyl med mindst et halogenatom, eller et lineært eller forgrenet C2-C6 alkynyl med mindst et halogenatom; Res' er et lineært eller forgrenet C1-C6 alkyl, et lineært eller forgrenet C1-C6 perhaloalkyl, et lineært eller forgrenet C2-C6 perhaloalkenyl, et lineært eller forgrenet C2-C6 perhaloalkynyl, et lineært eller forgrenet C1-C6 alkyl med mindst et halogenatom, et lineært eller forgrenet C2-C6 alkenyl med mindst et halogenatom, eller et lineært eller forgrenet C2-C6 alkynyl med mindst et halogenatom; hver R9a og R9b, hvor til stede, er uafhængigt hydrogen eller C1-C6 lineær eller forgrenet alkyl; RIO og Ril er uafhængigt hydrogen, -S02Rcs·, C1-C6 lineær eller forgrenet alkyl, C2-C6 lineær eller forgrenet alkenyl, C3-C6 cycloalkyl, eller C3-C6 cycloalkenyl; eller er taget sammen med N til hvilke de er fastgjort for at danne en C3-C6 heterocykel, pyrrolidinon, piperidinon, oxazolidinon, oxazinanon, imidazolidinon, tetrahydropyrimidin-2(lH)-on, et lA6,2-thiazolidin-l,l-dion, et l,2A6,3-oxathiazolidin-2,2-dion, eller et lA6,2,5-thiadiazolidin-l,l-dion; X er et heteroatom valgt fra S, O; eller NRb hvor Rb er hydrogen, et C1-C6 lineær eller forgrenet alkyl, eller et C3-C6 cycloalkyl; og Hver m og n er 1, 2 eller 3; eller (b) formlerne (Ila) eller (Ilb):
eller et farmaceutisk acceptabelt salt deraf, hvor: (i) A er en del valgt fra gruppen bestående af:
hvor ringen indeholdende X er forbundet til ring A ved enhver tilgængelig position på ring A; eller (ii) hvor A er en del valgt fra gruppen bestående af:
hver Rc4, Res, og Res, er uafhængigt hydrogen, halogen, CN, CFa, OH, C1-C3 lineær eller forgrenet alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C1-C3 lineær eller forgrenet alkoxy, -CO2H, -CONR10R11, eller - NHCONH2; eller er taget med Rc7 for at danne delen
Rc7 er hydrogen, C1-C6 lineær eller forgrenet alkyl, C1-C6 lineær eller forgrenet hydroxyalkyl, -(CR9aR9b)mNR10Rll, -C02-Alkyl, -(CRR9aR9b)mO-Alkyl, - (CR9aR9b)m0P03Na2, -(CR9aR9b)mO(CR9aR9b)nO“Alkyl, -(CR9aR9b)m0(C = 0)_Alkyl, -(CR9aR9b)m0(CR9aR9b)n(C=0)-Alkyl, -(C=0)CH=CH2, -S02Rc8'; eller er taget med en af Rc4, Res eller Res for at danne delen
Rce er et lineært eller forgrenet C1-C6 perhaloalkyl, et lineært eller forgrenet C2-C6 perhaloalkenyl, et lineært eller forgrenet C2-C6 perhaloalkynyl, et lineært eller forgrenet C1-C6 alkyl med mindst et halogenatom, et lineært eller forgrenet C2-C6 alkenyl med mindst et halogenatom, eller et lineært eller forgrenet C2-C6 alkynyl med mindst et halogenatom; Rce' er et lineært eller forgrenet C1-C6 alkyl, et lineært eller forgrenet C1-C6 perhaloalkyl, et lineært eller forgrenet C2-C6 perhaloalkenyl, et lineært eller forgrenet C2-C6 perhaloalkynyl, et lineært eller forgrenet C1-C6 alkyl med mindst et halogenatom, et lineært eller forgrenet C2-C6 alkenyl med mindst et halogenatom, eller et lineært eller forgrenet C2-C6 alkynyl med mindst et halogenatom; Hver Rea og R9t>, hvor til stede, er uafhængigt hydrogen eller C1-C6 lineær eller forgrenet alkyl; RIO og Ril er uafhængigt hydrogen, -SO2RC8', C1-C6 lineær eller forgrenet alkyl, C2-C6 lineær eller forgrenet alkenyl, C3-C6 cycloalkyl, eller C3-C6 cycloalkenyl; eller er taget sammen med N til hvilke de er fastgjort for at danne en C3-C6 heterocykel, pyrrolidinon, piperidinon, oxazolidinon, oxazinanon, imidazolidinon, tetrahydropyrimidin-2(lH)-on, et lA6,2-thiazolidin-l,l-dion, et l,2A6,3-oxathiazolidin-2,2-dion, eller et lA6,2,5-thiadiazolidin-l,l-dion; X er et heteroatom valgt fra S, O; eller NRb hvor Rb er hydrogen, et C1-C6 lineær eller forgrenet alkyl, eller et C3-C6 cycloalkyl; og Hver m og n er 1, 2 eller 3.
2. Forbindelsen ifølge krav 1, hvor X er S eller NRb, hvor Rb er (a) et lineært eller forgrenet C1-C6 alkyl, (b) methyl, ethyl, n-propyl, n-butyl, n-pentyl, eller n-hexyl; eller (c) iso-propyl, iso-pentyl, eller tert-butyl.
3. Forbindelsen ifølge krav 1 eller krav 2, hvor phenylringen indeholdende grupperne Rc4, Res, Rce, og -NRc7S02Rcs, er en del valgt fra:
4. Forbindelsen ifølge et hvilket som helst af kravene 1-3, hvor hver Rc4, Res og Rce, er uafhængigt hydrogen, halogen, CN, CF3, OH, C1-C3 lineær eller forgrenet alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C1-C3 lineær eller forgrenet alkoxy, -CO2H, -CONRlORll, eller -NHCONH2; eller er taget med Rc7 for at danne delen
5. Forbindelsen ifølge et hvilket som helst af kravene 1-4, hvor: (a) mindst en af Rc4, Res og Rce er hydrogen; (b) to af Rc4, Res og Rc6 er hydrogen; (c) hver Rc4, Res og Rc6 er hydrogen; (d) mindst en af Rc4, Res og Rc6 er halogen; (e) to af Rc4, Res og Rc6 er halogen (f) hver Rc4, Res og Rc6 er halogen (g) en af Rc4, Res og Rce er hydrogen, og de resterende to af Rc4, Res og Rc6 er halogen; (h) hvor to af Rc4, Res og Rce er hydrogen, og den resterende af Rc4, Res og Rce er halogen; eller (i) Rc4, Res og Rce hver er halogen.
6. Forbindelsen ifølge et hvilket som helst af kravene 1-5, hvor Rc4, Res og Rce hver er halogen.
7. Forbindelsen ifølge krav 1, hvor: A er en del valgt fra
X er S, og phenylringen indeholdende grupperne Rc4, Res, Rce, og -NRC7SO2RC8, er en del valgt fra:
8. Forbindelsen ifølge krav 1, hvor forbindelsen er valgt fra gruppen bestående af: l,l,l-trifluor-N-(4-(2-(2-propylpyridin-4-yl)thiazol-4- yl)phenyl)methansulfonamid; 1.1.1- trifluor-N-(3-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenyl)methansulfonamid; N-(3-chlor-4-(2-(l-isobutyl-lH-pyrazol-5-yl)thiazol-4-yl)phenyl)-l,l,l- trifluormethansulfonamid; N-(3-chlor-4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenyl)-l,l,l- trifluormethansulfonamid; N-(4-(2-(2-tert-butylpyridin-4-yl)thiazol-4-yl)-3-chlorphenyl)-l,l,l- trifluormethansulfonamid; N-(3-chlor-4-(2-(l,2-dimethyl-lH-pyrrolo[2,3-b]pyridin-4-yl)thiazol-4-yl)phenyl)-l,l,l-trifluormethansulfonamid ; N-(3-chlor-4-(2-(l-propyl-lH-pyrrolo[2,3-b]pyridin-4-yl)thiazol-4- yl)phenyl)-l,l,l-trifluormethansulfonamid; N-(3-chlor-4-(2-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-7-yl)thiazol-4- yl)phenyl)-l,l,l-trifluormethansulfonamid; N-(3-chlor-4-(2-(3-propyl-3H-imidazo[4,5-b]pyridin-7-yl)thiazol-4- yl)phenyl)-l,l,l-trifluormethansulfonamid; N-(4-(2-(3H-imidazo[4,5-b]pyridin-7-yl)thiazol-4-yl)-3-chlorphenyl)-1,1,1-trifluormethansulfonamid; N-(3-chlor-4-(2-(l,2-dipropyl-lH-pyrrolo[2,3-b]pyridin-4-yl)thiazol-4- yl)phenyl)-l,l,l-trifluormethansulfonamid; N-(4-(2-(6-(butylamino)-2-isobutylpyrimidin-4-yl)thiazol-4-yl)-3- chlorphenyl)-l,l,l-trifluormethansulfonamid; N-(3-chlor-4-(2-(6-(dibutylamino)-2-isobutylpyrimidin-4-yl)thiazol-4- yl)phenyl)-l,l,l-trifluormethansulfonamid; N-(4-(2-(6-amino-2-isobutylpyrimidin-4-yl)thiazol-4-yl)-3-chlorphenyl)- 1.1.1- trifluormethansulfonamid; N-(4-(2-(2-aminopyrimidin-4-yl)thiazol-4-yl)-3-chlorphenyl)-l,l,l- trifluormethansulfonamid; N-(3-chlor-4-(2-(2-(propylamino)pyrimidin-4-yl)thiazol-4-yl)phenyl)-l,l,l- trifluormethansulfonamid; N-(3-chlor-4-(2-(2-(dibutylamino)pyrimidin-4-yl)thiazol-4-yl)phenyl)-1,1,1-trifluormethansulfonamid; N-(3-chlor-4-(2'-propyl-2,4'-bithiazol-4-yl)phenyl)-l,l,l- trifluormethansulfonamid; N-(3-chlor-4-(2-(5-propyl-l,2,4-thiadiazol-3-yl)thiazol-4-yl)phenyl)-l,l,l- trifluormethansulfonamid; N-(3-chlor-4-(2-(5-propyl-l,2,4-oxadiazol-3-yl)thiazol-4-yl)phenyl)-l,l,l- trifluormethansulfonamid; N-(3-chlor-4-(2'-propyl-2,5'-bithiazol-4-yl)phenyl)-l,l,l- trifluormethansulfonamid; N-(3-chlor-4-(2-(5-propyl-l,3,4-thiadiazol-2-yl)thiazol-4-yl)phenyl)-l,l,l- trifluormethansulfonamid; N-(3-chlor-4-(2-(5-propyl-l,3,4-oxadiazol-2-yl)thiazol-4-yl)phenyl)-l,l,l- trifluormethansulfonamid; N-(3-chlor-4-(2-(l-isobutyl-6-oxo-l,6-dihydrc>pyridin-3-yl)thiazol-4- yl)phenyl)-l,l,l-trifluormethansulfonamid; N-(3-chlor-4-(2-(4-fluor-3-isobutylphenyl)thiazol-4-yl)phenyl)-1,1,1-trifluormethansulfonamid; N-(2-brom-3-chlor-4-(2-(2-isobutylpyridin-4-yl)thiazol-4-yl)phenyl)-l,l,l- trifluormethansulfonamid; N-(3,5-dichlor-4-(2-(2-isobutylpyridin-4-yl)thiazol-4-yl)phenyl)-l,l,l- trifluormethansulfonamid; 1.1.1- trifluor-N-(4-(2-(2-isobutylpyridin-4-yl)thiazol-4-yl)-2-(trifluormethyl)phenyl)methansulfonamid; N-(2-cyclopropyl-4-(2-(2-isobutylpyridin-4-yl)thiazol-4-yl)phenyl)-l,l,l- trifluormethansulfonamid; 1.1.1- trifluor-N-(4-(2-(2-isobutylpyridin-4-yl)thiazol-4-yl)-2-methylphenyl)methansulfonamid; 1.1.1- trifluor-N-(4-(2-(2-isobutylpyridin-4-yl)thiazol-4-yl)-2-isopropylphenyl)methansulfonamid; N-(2-ethynyl-4-(2-(2-isobutylpyridin-4-yl)thiazol-4-yl)phenyl)-1,1,1-trifluormethansulfonamid; N-(2-brom-3-ethynyl-4-(2-(2-isobutylpyridin-4-yl)thiazol-4-yl)phenyl)- 1.1.1- trifluormethansulfonamid; N-(2-brom-6-chlor-4-(2-(2-isobutylpyridin-4-yl)thiazol-4-yl)phenyl)-1,1,1-trifluormethansulfonamid; N-(2-chlor-4-(2-(2-isobutylpyridin-4-yl)thiazol-4-yl)-6-methylphenyl)- 1.1.1- trifluormethansulfonamid; N-(4-(4-(2-tert-butylpyridin-4-yl)-l-methyl-lH-imidazol-2-yl)-3- chlorphenyl)-l,l,l-trifluormethansulfonamid; N-(3-chlor-4-(2-(2-isobutylpyridin-4-yl)thiazol-4-yl)phenyl)-l,l,l- trifluormethansulfonamid; N-(2-brom-4-(l-methyl-2-(2-propylpyridin-4-yl)-lH-imidazol-4-yl)phenyl)- 1.1.1- trifluormethansulfonamid; N-(2-brom-3-chlor-4-(2-(2-prc>pylpyridin-4-yl)-lH-imidazol-4-yl)phenyl)- 1.1.1- trifluormethansulfonamid; N-(2-brom-5-chlor-4-(l-methyl-2-(2-propylpyridin-4-yl)-lH-imidazol-4- yl)phenyl)-l,l,l-trifluormethansulfonamid; N-(4-(4-(2-tert-butylpyridin-4-yl)oxazol-2-yl)-3-chlorphenyl)-l,l,l- trifluormethansulfonamid; N-(4-(2-(2-tert-butylpyridin-4-yl)oxazol-4-yl)-3-chlorphenyl)-l,l,l- trifluormethansulfonamid; N-(3-chlor-4-(2-(2-(dimethylamino)pyridin-4-yl)thiazol-4-yl)phenyl)-l,l,l- trifluormethansulfonamid; N-(3-chlor-4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenyl)-N- (trifluormethylsulfonyl)acrylamid; N-(3-chlor-4-(2-(2-(methylsulfonamido)pyridin-4-yl)thiazol-4-yl)phenyl)- 1.1.1- trifluormethansulfonamid; N-(3-chlor-4-(2-(2-(3,3,3-trifluorpropyl)pyridin-4-yl)thiazol-4-yl)phenyl)- 1.1.1- trifluormethansulfonamid; 1.1.1- trifluor-N-(2-hydroxy-4-(2-(2-isobutylpyridin-4-yl)thiazol-4-yl)phenyl)methansulfonamid; 1.1.1- trifluor-N-(2-hydroxy-4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenyl)methansulfonamid; N-(4-(2-(2-tert-butylpyridin-4-yl)thiazol-4-yl)-2-hydroxyphenyl)-l,l,l- trifluormethansulfonamid; 1.1.1- trifluor-N-(2-methoxy-4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenyl)methansulfonamid; 1.1.1- trifluor-N-(4-(2-(2-isobutylpyridin-4-yl)thiazol-4-yl)-2-methoxyphenyl)methansulfonamid; N-(4-(2-(2-tert-butylpyridin-4-yl)thiazol-4-yl)-2-methoxyphenyl)-l,l,l- trifluormethansulfonamid; 1.1.1- trifluor-N-(4-(2-(2-isobutylpyridin-4-yl)thiazol-4-yl)-3-(trifluormethyl)phenyl)methansulfonamid; N-(3-chlor-4-(2-(2-neopentylpyridin-4-yl)thiazol-4-yl)phenyl)-l,l,l- trifluormethansulfonamid; 6-(2-(2-isobutylpyridin-4-yl)thiazol-4-yl)-3- (trifluormethylsulfonyl)benzo[d]oxazol-2(3H)-on; N-(3-chlor-4-(2-(2-isobutylpyridin-4-yl)thiazol-4-yl)phenyl)-l, 1,2,2,2-pentafluorethanesulfonamid; 1.1.1- trifluor-N-(2-methoxy-4- {2-[2-(2-methylpropyl)pyridin-4-yl]-l ,3-thiazol-4-yl>phenyl)methansulfonamid; 1.1.1- trifluor-N-{2-methoxy-4-[2-(2-propylpyridin-4-yl)-l,3-thiazol-4-yl]phenyl>methansulfonamid; N-{4-[2-(2-tert-butylpyridin-4-yl)-l,3-thiazol-4-yl]-2-methoxyphenyl>- 1.1.1- trifluormethansulfonamid; N-{4-[2-(2-benzylpyridin-4-yl)-l,3-thiazol-4-yl]-3-chlorphenyl>-l,l,l- trifluormethansulfonamid; N-{4-[2-(2-aminopyridin-4-yl)-l,3-thiazol-4-yl]-3-chlorphenyl>-l,l,l- trifluormethansulfonamid; N- {3-chlor-4-[2-(2-methansulfonamidopyridin-4-yl)-l,3-thiazol-4-yl]phenyl}-l,l,l-trifluormethansulfonamid; l,l,l-trifluor-N-{2-hydroxy-4-[2-(2-propylpyridin-4-yl)-l,3-thiazol-4- yl]phenyl}methansulfonamid; N-(3-chlor-4-{2-[2-(3,3,3-trifluorprc>pyl)pyridin-4-yl]-l,3-thiazol-4- yl}phenyl)-l,l,l-trifluormethansulfonamid; N-(4-{2-[2-(2,2-dimethylpropyl)pyridin-4-yl]-l,3-thiazol-4-yl} -2-methoxyphenyl)-l,l,l-trifluormethansulfonamid; N-{3-chlor-4-[2-(2-trifluormethansulfonamidopyridin-4-yl)-l,3-thiazol-4-yl] phenyl}-1,1,1 -trifluormethansulfonamid; N-(3-chlor-4-(2-(4-(piperid in-l-carbonyl)phenyl)thiazol-4-yl)phenyl)-1,1,1-trifluormethansulfonamid; N-(3-chlor-4-{2-[l-(3-methylbutyl)-lH-pyrazol-5-yl]-l,3-thiazol-4- yl}phenyl)-l,l,l-trifluormethansulfonamid; N- {4-[5 -(2-tert-butylpyridin-4-yl)thiophen-3 -yl] -3 -chlorphenyl}methansulfonamid; N-(3-chlor-4-{2-[2-(cyclohexylmethyl)pyridin-4-yl]-l,3-thiazol-4- yl}phenyl)-l,l,l-trifluormethansulfonamid; N-{3-chlor-4-[2-(naphthalen-l-yl)-l,3-thiazol-4-yl]phenyl} -1,1,1-trifluormethansulfonamid; N-{3-chlor-4-[2-(lH-indol-6-yl)-l,3-thiazol-4-yl]phenyl}-l,l,l- trifluormethansulfonamid; N-(4- {2-[3-(benzyloxy)-4-(trifluormethyl)phenyl]-l ,3-thiazol-4-yl} -3-chlorphenyl)-l,l,l-trifluormethansulfonamid; N-{3-chlor-4-[2-(2-phenylphenyl)-l,3-thiazol-4-yl]phenyl}-l,l,l- trifluormethansulfonamid; N-{3-chlor-4-[2-(isoquinolin-4-yl)-l,3-thiazol-4-yl]phenyl} -1,1,1-trifluormethansulfonamid; N-(3-chlor-4-{2-[2-(4-methylpiperazin-l-yl)pyridin-4-yl]-l,3-thiazol-4- yl}phenyl)-l,l,l-trifluormethansulfonamid; N-{3 -chlor-4- [2-(dimethyl-l ,2-oxazol-4-yl)-l,3-thiazol-4-yl]phenyl}- 1.1.1- trifluormethansulfonamid; N- {3-[4-(2-chlor-4-trifluormethansulfonamidophenyl)-l ,3-thiazol-2-yl]phenyl> -4-methylbenzen-l-sulfonamid; N-{3-chlor-4-[2-(3,4-dimethoxyphenyl)-l,3-thiazol-4-yl]phenyl}-l,l,l- trifluormethansulfonamid; N-{3-chlor-4-[2-(lH-indol-4-yl)-l,3-thiazol-4-yl]phenyl}-l,l,l- trifluormethansulfonamid; N-(3-chlor-4-{2-[4-fluor-2-(trifluormethyl)phenyl]-l,3-thiazol-4- yl}phenyl)-l,l,l-trifluormethansulfonamid; N-{3-chlor-4-[2-(2,3-dihydro-l-benzofuran-5-yl)-l,3-thiazol-4-yl]phenyl>- 1.1.1- trifluormethansulfonamid; N-(3-chlor-4-{2-[3-(hydroxymethyl)phenyl]-l,3-thiazol-4-yl>phenyl)- 1.1.1- trifluormethansulfonamid; N-(3-chlor-4-{2-[2-(hydroxymethyl)phenyl]-l,3-thiazol-4-yl}phenyl)- 1.1.1- trifluormethansulfonamid; N-(3-chlor-4-{2-[2-(piperidin-l-yl)pyridin-4-yl]-l,3-thiazol-4-yl>phenyl)- 1.1.1- trifluormethansulfonamid; N-{3-chlor-4-[2-(3-methylpyridin-4-yl)-l,3-thiazol-4-yl]phenyl> -1,1,1-trifluormethansulfonamid; N-[3-chlor-4-(2-{lH-pyrrolo[2,3-b]pyridin-4-yl>-l,3-thiazol-4-yl)phenyl]- 1.1.1- trifluormethansulfonamid; N-(3-chlor-4-{2-[3-(piperidin-l-yl)phenyl]-l,3-thiazol-4-yl>phenyl)-l,l,l- trifluormethansulfonamid; N-[3-chlor-4-(2-{5-fluor-lH-pyrrolo[2,3-b]pyridin-4-yl>-l,3-thiazol-4- yl)phenyl]-l,l,l-trifluormethansulfonamid; N-{4-[2-(l-benzothiophen-3-yl)-l,3-thiazol-4-yl]-3-chlorphenyl>-l,l,l- trifluormethansulfonamid; N-(3-chlor-4-{2-[4-fluor-2-(pyrrolidin-l-ylmethyl)phenyl]-l,3-thiazol-4- yl>phenyl)-l,l,l-trifluormethansulfonamid; N-(3-chlor-4-{2-[2-(cyclopentylamino)pyridin-4-yl]-l,3-thiazol-4- yl>phenyl)-l,l,l-trifluormethansulfonamid; N-{3-chlor-4-[2-(lH-indol-3-yl)-l,3-thiazol-4-yl] phenyl}-1,1,1-trifluormethansulfonamid; N-(3-chlor-4-(2-(quinolin-4-yl)thiazol-4-yl)phenyl)-1,1,1-trifluormethansulfonamid; N-(3-chlor-4-(2-(2-chlorpyridin-4-yl)thiazol-4-yl)phenyl)-1,1,1-trifluormethansulfonamid; N-(2-brom-4-(2-(2-tert-butylpyridin-4-yl)thiazol-4-yl)-3-chlorphenyl)- 1.1.1- trifluormethansulfonamid; N-(2-brom-4-(2-(2-propylpyridin-4-yl)-lH-imidazol-4-yl)phenyl)-l,l,l- trifluormethansulfonamid; N-(2-brom-4-(2-(2-tert-butylpyridin-4-yl)thiazol-4-yl)-3-chlorphenyl)- 1.1.1- trifluor-N-(2-hydroxyethyl)methansulfonamid; N-(4-(2-(2-tert-butylpyridin-4-yl)thiazol-4-yl)-3-chlorphenyl)-l,l,l-trifluor- N-(2-(2-oxopyrrolidin-l-yl)ethyl)methansulfonamid; N-(4-(2-(2-tert-butylpyridin-4-yl)thiazol-4-yl)-3-chlorphenyl)-l,l,l-trifluor- N-(2-(2-oxooxazolidin-3-yl)ethyl)methansulfonamid; N-(4-(2-(2-tert-butylpyridin-4-yl)thiazol-4-yl)-3-chlorphenyl)-l,l,l-trifluor- N-(2-(2-oxoimidazolidin-l-yl)ethyl)methansulfonamid; N-(2-brom-4-(2-(2-(piperidin-l-yl)pyridin-4-yl)-lH-imidazol-4-yl)phenyl)- 1.1.1- trifluormethansulfonamid; 2-(N-(4-(2-(2-tert-butylpyridin-4-yl)thiazol-4-yl)-3-chlorphenyl)-l,l,l-trifluormethylsulfonamido)ethyl acetat; (2-(N-(4-(2-(2-tert-butylpyridin-4-yl)thiazol-4-yl)-3-chlorphenyl)-l,l,l-trifluormethylsulfonamido)ethoxy)methyl acetat; N- {4-[2-(2-tert-butylpyridin-4-yl)-l,3-thiazol-4-yl]-3-chlorphenyl>-N-(2- {[4-(3-chlorphenyl)-2-oxo-l,3,2A5-dioxaphosphinan-2-yl]oxy}ethyl)-l,l,l- trifluormethansulfonamid; (N-(4-(2-(2-tert-butylpyridin-4-yl)thiazol-4-yl)-3-chlorphenyl)-l,l,l-trifluormethylsulfonamido)methyl acetat; N-(4-(2-(2-tert-butylpyridin-4-yl)thiazol-4-yl)-3-chlorphenyl)-l,l,l-trifluor- N-(methoxymethyl)methansulfonamid; N-{4-[2-(2-tert-butylpyridin-4-yl)-l,3-thiazol-4-yl]-3-chlorphenyl}-N-({[4- (3-chlorphenyl)-2-oxo-l,3,2A5-dioxaphosphinan-2-yl]oxy}methyl)-l,l,l- trifluormethansulfonamid; methyl 4-(2-(2-tert-butylpyridin-4-yl)thiazol-4-yl)-3-chlorphenyl(trifluormethylsulfonyl)carbamat; sodium (N-(4-(2-(2-tert-butylpyridin-4-yl)thiazol-4-yl)-3-chlorphenyl)- 1.1.1- trifluormethylsulfonamido)methyl phosphat; l-(N-(3-chlor-4-(2-(2-isobutylpyridin-4-yl)thiazol-4-yl)phenyl)-l,l,l-trifluormethylsulfonamido)ethyl isobutyrat; N-(3-chlor-4-(2-(2-isobutylpyridin-4-yl)thiazol-4-yl)phenyl)-l,l,l-trifluor- N-(2-(2-oxooxazolidin-3-yl)ethyl)methansulfonamid; N-(4-(2-(2-tert-butylpyridin-4-yl)thiazol-4-yl)-3-chlorphenyl)-l,l,l-trifluor- N-(2-hydroxyethyl)methansulfonamid; N-(3-chlor-4-(2-(2-isobutylpyridin-4-yl)thiazol-4-yl)phenyl)-l,l,l-trifluor- N-(2-(pyrrolidin-l-yl)ethyl)methansulfonamid; N-(3-chlor-4-(2-(2-isobutylpyridin-4-yl)thiazol-4-yl)phenyl)-N-(2- (diethylamino)ethyl)-l,l,l-trifluormethansulfonamid; N-(3-chlor-4-(2-(2-isobutylpyridin-4-yl)thiazol-4-yl)phenyl)-N-(2- (dimethylamino)ethyl)-l,l,l-trifluormethansulfonamid; 1.1.1- trifluor-N-(3-fluor-4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenyl)methansulfonamid; N-(3-chlor-4-(2-(2-isobutylpyridin-4-yl)-lH-imidazol-4-yl)phenyl)-l,l,l- trifluormethansulfonamid; N-(3-chlor-4-(2-(2-isobutylpyridin-4-yl)thiazol-4-yl)phenyl)-l,l,l-trifluor- N-(2-hydroxyethyl)methansulfonamid; N-(3-chlor-4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenyl)-l,l,l-trifluor-N- methylmethansulfonamid; 1.1.1- trifluor-N-(3-(2-(2-isobutylpyridin-4-yl)thiazol-4-yl)phenyl)methansulfonamid; N-(2-brom-4-(2-(2-isobutylpyridin-4-yl)thiazol-4-yl)phenyl)-l,l,l- trifluormethansulfonamid; 1.1.1- trifluor-N-methyl-N-(4-(2-(2-prc>pylpyridin-4-yl)thiazol-4-yl)phenyl)methansulfonamid; N-(4-(2-(2-butylpyridin-4-yl)thiazol-4-yl)phenyl)-1,1,1-trifluormethansulfonamid 1.1.1- trifluor-N-(4-(2-(2-(methoxymethyl)pyridin-4-yl)thiazol-4-yl)phenyl)methansulfonamid; N-(4-(2-(4,6-dipropylpyridin-2-yl)thiazol-4-yl)phenyl)-1,1,1-trifluormethansulfonamid; 1.1.1- trifluor-N-(4-(2-(4-prc>pylpyridin-2-yl)thiazol-4-yl)phenyl)methansulfonamid; N-(4-(2-(2,6-dipropylpyridin-3-yl)thiazol-4-yl)phenyl)-1,1,1-trifluormethansulfonamid; N-(4-(2-(2-(cyclohexylmethyl)pyridin-4-yl)thiazol-4-yl)phenyl)-1,1,1-trifluormethansulfonamid; 1.1.1- trifluor-N-(4-(2-(2-isobutylpyridin-4-yl)thiazol-4-yl)-3-methoxyphenyl)methansulfonamid; N-(3-chlor-4-(2-(2-((trifluormethylsulfonyl)methyl)pyridin-4-yl)thiazol-4- yl)phenyl)-l,l,l-trifluormethansulfonamid; N-(4-(2-(l H-pyrrolo[2,3-b] pyrid in-4-yl)thiazol-4-yl)-3-chlorphenyl)-1,1,1-trifluormethansulfonamid; N-(3-chlor-4-(2-(2-propyl-3H-imidazo[4,5-b]pyridin-7-yl)thiazol-4- yl)phenyl)-l,l,l-trifluormethansulfonamid; 5-(4-(2-chlor-4-(trifluormethylsulfonamido)phenyl)thiazol-2-yl)-N- cydopropyl-2-fluorbenzamid; 5-(4-(2-chlor-4-(trifluormethylsulfonamido)phenyl)thiazol-2-yl)-N- cyclohexyl-2-fluorbenzamid; N-(4-(2-(lH-indol-4-yl)thiazol-4-yl)-3-chlorphenyl)-l,l,l- trifluormethansulfonamid; N-(3-chlor-4-(2-(3-(piperid in-l-yl)phenyl)thiazol-4-yl)phenyl)-1,1,1-trifluormethansulfonamid; N-(3-chlor-4-(2-(2-(piperidin-l-yl)pyridin-4-yl)thiazol-4-yl)phenyl)-1,1,1-trifluormethansulfonamid; N-(2-brom-4-(2-(2-tert-butylpyridin-4-yl)-lH-imidazol-4-yl)phenyl)-1,1,1-trifluormethansulfonamid; N-(2-chlor-4-(2-(2-propylpyridin-4-yl)-lH-imidazol-4-yl)phenyl)-l,l,l- trifluormethansulfonamid; N-(2-brom-5-chlor-4-(2-(2-propylpyridin-4-yl)-lH-imidazol-4-yl)phenyl)- 1,1,1-trifluormethansulfonamid; og N-(2-brom-4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenyl)-1,1,1-trifluormethansulfonamid.
9. Forbindelsen ifølge krav 1, hvor forbindelsen er N-(3-chlor-4-(2-(2-isobutylpyridin-4-yl)thiazol-4-yl)phenyl)-l,l,l-trifluormethansulfonamid.
10. Farmaceutisk sammensætning omfattende en forbindelse ifølge et hvilket som helst af kravene 1-9 og et farmaceutisk acceptabelt vehikel.
11. Forbindelsen ifølge et hvilket som helst af kravene 1-9 til anvendelse i behandling af en stofskifteforstyrrelse eller en hyperproliferativ lidelse.
12. Forbindelsen til anvendelse ifølge krav 11, hvor den hyperproliferative lidelse er kræft.
13. Forbindelsen til anvendelse ifølge krav 12, hvor kræften er brystkræft, prostatakræft, eller æggestokskræft.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2816MU2013 | 2013-08-28 | ||
IN3497MU2013 | 2013-11-04 | ||
PCT/US2014/053215 WO2015031650A1 (en) | 2013-08-28 | 2014-08-28 | Heterocyclic compounds and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3038622T3 true DK3038622T3 (da) | 2018-07-16 |
Family
ID=52584081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14839213.7T DK3038622T3 (da) | 2013-08-28 | 2014-08-28 | Heterocykliske forbindelser og fremgangsmåder til anvendelse |
Country Status (28)
Country | Link |
---|---|
US (1) | US9670172B2 (da) |
EP (1) | EP3038622B1 (da) |
JP (2) | JP2017506618A (da) |
KR (1) | KR20160067841A (da) |
CN (1) | CN106029072A (da) |
AU (1) | AU2014312245B2 (da) |
CA (1) | CA2922346A1 (da) |
CR (1) | CR20160136A (da) |
DK (1) | DK3038622T3 (da) |
EC (1) | ECSP16012582A (da) |
ES (1) | ES2676585T3 (da) |
HR (1) | HRP20181017T1 (da) |
HU (1) | HUE039624T2 (da) |
IL (1) | IL244268A0 (da) |
LT (1) | LT3038622T (da) |
MX (1) | MX2016002443A (da) |
NO (1) | NO20160470A1 (da) |
PH (1) | PH12016500382A1 (da) |
PL (1) | PL3038622T3 (da) |
PT (1) | PT3038622T (da) |
RS (1) | RS57338B1 (da) |
RU (1) | RU2016111138A (da) |
SA (1) | SA516370641B1 (da) |
SG (2) | SG10201806370QA (da) |
SI (1) | SI3038622T1 (da) |
TR (1) | TR201809185T4 (da) |
UA (1) | UA116675C2 (da) |
WO (1) | WO2015031650A1 (da) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9873689B2 (en) | 2014-11-07 | 2018-01-23 | Fgh Biotech, Inc. | Synthesis of fatostatin based polycyclic compounds |
WO2016105491A1 (en) | 2014-12-23 | 2016-06-30 | Fgh Biotech | Compositions of fatostatin based heterocyclic compounds and uses thereof |
EP3265457A1 (en) | 2015-03-04 | 2018-01-10 | Medivation Technologies LLC | Sterol regulatory element-binding proteins (srebps) inhibitors |
US10183015B2 (en) | 2015-03-04 | 2019-01-22 | Medivation Technologies Llc | Heterocyclic compounds and methods of use |
CN105732355A (zh) * | 2016-04-07 | 2016-07-06 | 戊言医药科技(上海)有限公司 | 1-(5-氟-2-碘苯基)乙酮的制备方法 |
CA3022395A1 (en) | 2016-04-29 | 2017-11-02 | Fgh Biotech, Inc. | Di-substituted pyrazole compounds for the treatment of diseases |
ES2932187T3 (es) * | 2016-09-07 | 2023-01-16 | Fgh Biotech Inc | Compuestos de pirazol disustituidos para el tratamiento de enfermedades |
WO2019046316A1 (en) * | 2017-08-28 | 2019-03-07 | Acurastem Inc. | PIKFYVE KINASE INHIBITORS |
TW201940165A (zh) | 2018-01-29 | 2019-10-16 | 美商卡普勒斯療法有限責任公司 | 包含6員中心環的srebp抑制劑 |
WO2020132700A1 (en) | 2018-12-21 | 2020-06-25 | Fgh Biotech Inc. | Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof |
WO2021154735A1 (en) * | 2020-01-27 | 2021-08-05 | Capulus Therapeutics, Llc | Srebp inhibitors comprising a thiophene central ring |
CN116041277A (zh) * | 2023-01-18 | 2023-05-02 | 中国药科大学 | 苯基和联苯基取代的五元杂环类化合物及其制备方法、药物组合物和应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3796764B2 (ja) * | 1995-01-25 | 2006-07-12 | コニカミノルタホールディングス株式会社 | 金属錯体化合物及び該化合物を用いた光記録媒体 |
AU765072B2 (en) * | 1998-02-09 | 2003-09-11 | 3-Dimensional Pharmaceuticals, Inc. | Heteroaryl amidines, methylamidines and guanidines as protease inhibitors, in particular as urokinase inhibitors |
US6291514B1 (en) * | 1998-02-09 | 2001-09-18 | 3-Dimensional Pharmaceuticals, Inc. | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors |
EP1084098A4 (en) * | 1998-06-09 | 2004-12-22 | Univ Connecticut | INHIBITORS OF THE ANANDAMIDE TRANSPORTER AS ANALGETIC AGENT |
MXPA02006016A (es) * | 1999-12-16 | 2002-12-05 | Schering Corp | Imidazoles sustituidos, antagonistas de los receptores y5 del neuropeptido y. |
TWI275589B (en) | 2000-06-22 | 2007-03-11 | Dow Agrosciences Llc | 2-(3,5-disubstituted-4-pyridyl)-4-(thienyl, thiazolyl or arylphenyl)-1,3-oxazoline compounds |
CA2525547C (en) | 2003-05-14 | 2012-07-03 | Torreypines Therapeutics, Inc. | Compounds and uses thereof in modulating amyloid beta |
CA2616377C (en) | 2005-07-26 | 2014-04-01 | David Alexander Learmonth | Nitrocatechol derivatives as comt inhibitors |
EP1922068A4 (en) | 2005-08-16 | 2010-08-11 | Icagen Inc | INHIBITORS OF VOLTAGE-CONTROLLED SODIUM CHANNELS |
US8229106B2 (en) | 2007-01-22 | 2012-07-24 | D.S.P. Group, Ltd. | Apparatus and methods for enhancement of speech |
US9212179B2 (en) | 2007-02-02 | 2015-12-15 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
US8207196B2 (en) * | 2007-02-02 | 2012-06-26 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
US9187485B2 (en) | 2007-02-02 | 2015-11-17 | Baylor College Of Medicine | Methods and compositions for the treatment of cancer and related hyperproliferative disorders |
US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
US20120040951A1 (en) * | 2008-12-30 | 2012-02-16 | Claudio Chuaqui | Heteroaryl compounds useful as raf kinase inhibitors |
US8242260B2 (en) * | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
WO2011085269A1 (en) | 2010-01-08 | 2011-07-14 | Selexagen Therapeutics, Inc. | Raf kinase inhibitors |
WO2012084678A1 (en) | 2010-12-23 | 2012-06-28 | Syngenta Participations Ag | Novel imidazoles useful as plant fungicides |
GB201116017D0 (en) | 2011-09-16 | 2011-10-26 | Univ Surrey | Bi-aromatic and tri-aromatic compounds as nadph oxidase inhibitors |
UY34540A (es) | 2011-12-23 | 2013-06-28 | Millennium Pharm Inc | Heteroarilos y usos de los mismos |
WO2014199164A1 (en) | 2013-06-12 | 2014-12-18 | Ampla Pharmaceuticals, Inc. | Diaryl substituted heteroaromatic compounds |
US20160193231A1 (en) | 2013-06-26 | 2016-07-07 | Rett Syndrome Research Trust | Rett syndrome and treatments therefore |
-
2014
- 2014-08-28 RS RS20180723A patent/RS57338B1/sr unknown
- 2014-08-28 TR TR2018/09185T patent/TR201809185T4/tr unknown
- 2014-08-28 UA UAA201603203A patent/UA116675C2/uk unknown
- 2014-08-28 HU HUE14839213A patent/HUE039624T2/hu unknown
- 2014-08-28 EP EP14839213.7A patent/EP3038622B1/en active Active
- 2014-08-28 US US14/471,977 patent/US9670172B2/en not_active Expired - Fee Related
- 2014-08-28 CR CR20160136A patent/CR20160136A/es unknown
- 2014-08-28 MX MX2016002443A patent/MX2016002443A/es unknown
- 2014-08-28 CN CN201480054063.3A patent/CN106029072A/zh active Pending
- 2014-08-28 PT PT148392137T patent/PT3038622T/pt unknown
- 2014-08-28 SG SG10201806370QA patent/SG10201806370QA/en unknown
- 2014-08-28 CA CA2922346A patent/CA2922346A1/en not_active Abandoned
- 2014-08-28 PL PL14839213T patent/PL3038622T3/pl unknown
- 2014-08-28 SG SG11201601486TA patent/SG11201601486TA/en unknown
- 2014-08-28 ES ES14839213.7T patent/ES2676585T3/es active Active
- 2014-08-28 LT LTEP14839213.7T patent/LT3038622T/lt unknown
- 2014-08-28 SI SI201430774T patent/SI3038622T1/en unknown
- 2014-08-28 AU AU2014312245A patent/AU2014312245B2/en not_active Ceased
- 2014-08-28 RU RU2016111138A patent/RU2016111138A/ru not_active Application Discontinuation
- 2014-08-28 DK DK14839213.7T patent/DK3038622T3/da active
- 2014-08-28 JP JP2016537857A patent/JP2017506618A/ja active Pending
- 2014-08-28 WO PCT/US2014/053215 patent/WO2015031650A1/en active Application Filing
- 2014-08-28 KR KR1020167007463A patent/KR20160067841A/ko not_active Application Discontinuation
-
2016
- 2016-02-24 IL IL244268A patent/IL244268A0/en unknown
- 2016-02-26 PH PH12016500382A patent/PH12016500382A1/en unknown
- 2016-02-28 SA SA516370641A patent/SA516370641B1/ar unknown
- 2016-03-18 NO NO20160470A patent/NO20160470A1/en not_active Application Discontinuation
- 2016-03-24 EC ECIEPI201612582A patent/ECSP16012582A/es unknown
-
2018
- 2018-07-02 HR HRP20181017TT patent/HRP20181017T1/hr unknown
-
2019
- 2019-03-20 JP JP2019052536A patent/JP2019089854A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3038622T3 (da) | Heterocykliske forbindelser og fremgangsmåder til anvendelse | |
CN113214287B (zh) | Hpk1抑制剂及其使用方法 | |
US10189826B2 (en) | Heterocyclic compounds and methods of use | |
JP7288527B2 (ja) | Prc2阻害剤 | |
US10183015B2 (en) | Heterocyclic compounds and methods of use | |
JP7217752B2 (ja) | Acss2阻害剤およびその使用方法 | |
JP2022532719A (ja) | Acss2阻害剤およびその使用方法 | |
JP6896701B2 (ja) | イミダゾリルアミド誘導体 | |
WO2011085269A1 (en) | Raf kinase inhibitors | |
JP2014513078A (ja) | パーキンソン病の治療方法及び治療用組成物 | |
WO2012125981A2 (en) | Raf kinase inhibitors | |
CA2933683A1 (en) | Wnt pathway modulators | |
EP2844660B1 (en) | Triazolopyridazine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof | |
CA2762620A1 (en) | Agent for treatment or prevention of diseases associated with activity of neurotrophic factors | |
WO2014172639A1 (en) | Raf kinase inhibitors |